Natural variation in interleukin-2 sensitivity influences regulatory T-cell frequency and function in individuals with long-standing type 1 diabetes

JHM Yang, AJ Cutler, RC Ferreira, JL Reading… - Diabetes, 2015 - Am Diabetes Assoc
JHM Yang, AJ Cutler, RC Ferreira, JL Reading, NJ Cooper, C Wallace, P Clarke, DJ Smyth…
Diabetes, 2015Am Diabetes Assoc
Defective immune homeostasis in the balance between FOXP3+ regulatory T cells (Tregs)
and effector T cells is a likely contributing factor in the loss of self-tolerance observed in type
1 diabetes (T1D). Given the importance of interleukin-2 (IL-2) signaling in the generation
and function of Tregs, observations that polymorphisms in genes in the IL-2 pathway
associate with T1D and that some individuals with T1D exhibit reduced IL-2 signaling
indicate that impairment of this pathway may play a role in Treg dysfunction and the …
Defective immune homeostasis in the balance between FOXP3+ regulatory T cells (Tregs) and effector T cells is a likely contributing factor in the loss of self-tolerance observed in type 1 diabetes (T1D). Given the importance of interleukin-2 (IL-2) signaling in the generation and function of Tregs, observations that polymorphisms in genes in the IL-2 pathway associate with T1D and that some individuals with T1D exhibit reduced IL-2 signaling indicate that impairment of this pathway may play a role in Treg dysfunction and the pathogenesis of T1D. Here, we have examined IL-2 sensitivity in CD4+ T-cell subsets in 70 individuals with long-standing T1D, allowing us to investigate the effect of low IL-2 sensitivity on Treg frequency and function. IL-2 responsiveness, measured by STAT5a phosphorylation, was a very stable phenotype within individuals but exhibited considerable interindividual variation and was influenced by T1D-associated PTPN2 gene polymorphisms. Tregs from individuals with lower IL-2 signaling were reduced in frequency, were less able to maintain expression of FOXP3 under limiting concentrations of IL-2, and displayed reduced suppressor function. These results suggest that reduced IL-2 signaling may be used to identify patients with the highest Treg dysfunction and who may benefit most from IL-2 immunotherapy.
Am Diabetes Assoc